Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Fluticasone furoate (nasal)

Intranasal corticosteroid

ATC code: R01AD12

Brand names: Flonase Sensimist, Veramyst

Updated · Methodology

Indications

A

Allergic rhinitis

First line

First-line for moderate-to-severe allergic rhinitis per ARIA 2020 alongside other intranasal corticosteroids (mometasone, budesonide, fluticasone propionate). Adults and children over 12: 2 sprays (55 mcg) per nostril once daily; children 6–11: 1 spray. Particularly effective with seasonal allergic rhinitis with conjunctivitis symptoms.

Sources

  1. AEMPS: Ficha técnica de Furoato de fluticasona (nasal) (2024)
  2. EAACI: ARIA guideline 2019 update on allergic rhinitis (2020)
  3. Clin Exp Allergy: Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. (2011)

ICD-10: J30.9 · ICD-11: CA08.0

A

Chronic rhinosinusitis

First line

First-line for chronic rhinosinusitis per EPOS 2020. Long-term use, usually several months.

Sources

  1. AEMPS: Ficha técnica de Furoato de fluticasona (nasal) (2024)
  2. Rhinology: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020)
  3. Cochrane Database Syst Rev: Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. (2016)
  4. Ann Otol Rhinol Laryngol: Effects of Fluticasone Furoate on Clinical and Immunological Outcomes (IL-17) for Patients With Nasal Polyposis Naive to Steroid Treatment. (2016)

ICD-10: J32.9 · ICD-11: CA0A

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Immune support and respiratory infection care

Not recommended

Nasal fluticasone furoate is used in children and adults for cold prevention and as nasal mucosal protection outside an allergic rhinitis or nasal polyps indication (approved indications: AEMPS Ficha Técnica, 2024). No clinical studies of prophylactic use for colds exist. The drug can cause nosebleeds, nasal septum perforation on long-term use, hoarseness, and with systemic absorption at high doses HPA axis suppression. If nasal fluticasone furoate was prescribed for cold prevention, consider seeking a second opinion.

Sources

  1. AEMPS: Ficha técnica de Furoato de fluticasona (nasal) (2024)
  2. Cochrane (Hemila and Chalker): Vitamin C for preventing and treating the common cold (2013)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A synthetic corticosteroid with high glucocorticoid receptor affinity and very low systemic bioavailability via the nasal route (under 0.5%). Compared with fluticasone propionate, improved receptor binding profile and longer tissue activity. Suppresses inflammatory mediator release and inflammatory cell migration into nasal mucosa. Onset 8 hours after first dose.

Safety

Contraindications

  • Fluticasone hypersensitivity
  • Untreated nasal mucosal infection
  • Recent nasal trauma or surgery (until healing)

Serious adverse effects

  • Nasal septum perforation (rare, with poor technique)
  • Nasal or pharyngeal candidiasis
  • Raised intraocular pressure and cataract with very long high-dose use

Common adverse effects

  • Epistaxis
  • Nasal mucosa irritation
  • Headache
  • Pharyngeal dryness

Pregnancy: can you take Fluticasone furoate (nasal)?

T1 use acceptable when symptomatic measures are insufficient. Budesonide has more pregnancy data and may be preferred.

Breastfeeding: can you take Fluticasone furoate (nasal)?

Systemic bioavailability is low; milk transfer is minimal. Compatible with breastfeeding.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Before first use, shake and prime with 6 sprays into the air. Blow the nose before each spray. Tilt head slightly forward, direct nozzle toward lateral nasal wall. Effect builds over 1–2 weeks of regular use; in seasonal rhinitis, start 1–2 weeks before pollen season. Systemic bioavailability under 0.5% – no adrenal suppression or growth slowing at standard doses.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Fluticasone furoate (nasal) used for?

Fluticasone furoate (nasal) is evaluated for the following indications with varying evidence strength: Chronic rhinosinusitis (evidence tier A), Allergic rhinitis (evidence tier A), Immune support and respiratory infection care (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Fluticasone furoate (nasal)?

Common side effects of Fluticasone furoate (nasal) (≥ 1 in 100): Epistaxis, Nasal mucosa irritation, Headache, Pharyngeal dryness. See the Safety section for uncommon and serious reactions.

Is Fluticasone furoate (nasal) safe during pregnancy?

T1 use acceptable when symptomatic measures are insufficient. Budesonide has more pregnancy data and may be preferred.

Is Fluticasone furoate (nasal) compatible with breastfeeding?

Systemic bioavailability is low; milk transfer is minimal. Compatible with breastfeeding.

Who should not take Fluticasone furoate (nasal)?

Fluticasone furoate (nasal) is contraindicated in: Fluticasone hypersensitivity; Untreated nasal mucosal infection; Recent nasal trauma or surgery (until healing). Full list in the Safety section.

Other drugs in this group

Interferon alpha-2b (nasal formulations), Mometasone furoate (nasal), Oxymetazoline, Pseudoephedrine, Xylometazoline